Literature DB >> 26296362

Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells.

JongWook Hong1, Nicholas P Tobin1, Helene Rundqvist1, Tian Li1, Marion Lavergne1, Yaiza García-Ibáñez1, Hanyu Qin1, Janna Paulsson1, Manuel Zeitelhofer1, Milena Z Adzemovic1, Ingrid Nilsson1, Pernilla Roswall1, Johan Hartman1, Randall S Johnson1, Arne Östman1, Jonas Bergh1, Mirjana Poljakovic1, Guillem Genové2.   

Abstract

BACKGROUND: Pericytes are members of the tumor stroma; however, little is known about their origin, function, or interaction with other tumor components. Emerging evidence suggest that pericytes may regulate leukocyte transmigration. Myeloid-derived suppressor cells (MDSC) are immature myeloid cells with powerful inhibitory effects on T-cell-mediated antitumor reactivity.
METHODS: We generated subcutaneous tumors in a genetic mouse model of pericyte deficiency (the pdgfb (ret/ret) mouse) and littermate control mice (n = 6-25). Gene expression profiles from 253 breast cancer patients (stage I-III) were evaluated for clinic-pathological parameters and survival using Cox proportional hazard ratios (HRs) and 95% confidence intervals (CIs) based on a two-sided Wald test.
RESULTS: We report that pericyte deficiency leads to increased transmigration of Gr1(+)/CD11b(+) cells in experimentally induced tumors. Pericyte deficiency produced defective tumor vasculature, resulting in a more hypoxic microenvironment promoting IL-6 upregulation in the malignant cells. Silencing IL-6 expression in tumor cells attenuated the observed differences in MDSC transmigration. Restoring the pericyte coverage in tumors abrogated the increased MDSC trafficking to pericyte-deficient tumors. MDSC accumulation in tumors led to increases in tumor growth and in circulating malignant cells. Finally, gene expression analysis from human breast cancer patients revealed increased expression of the human MDSC markers CD33 and S100A9 with concomitant decreased expression of pericyte genes and was associated with poor prognosis (HR = 1.88, 95% CI = 1.08 to 3.25, P = .03).
CONCLUSIONS: Our data uncovers a novel paracrine interaction between tumor pericytes and inflammatory cells and delineates the cellular events resulting in the recruitment of MDSC to tumors. Furthermore, we propose for the first time a role for tumor pericytes in modulating the expression of immune mediators in malignant cells by promoting a hypoxic microenvironment.
© The Author 2015. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26296362      PMCID: PMC6592827          DOI: 10.1093/jnci/djv209

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  26 in total

Review 1.  Exercise as Adjunct Therapy in Cancer.

Authors:  Kathleen A Ashcraft; Allison Betof Warner; Lee W Jones; Mark W Dewhirst
Journal:  Semin Radiat Oncol       Date:  2019-01       Impact factor: 5.934

Review 2.  Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance.

Authors:  Pritish Nilendu; Sachin C Sarode; Devashree Jahagirdar; Ishita Tandon; Shankargouda Patil; Gargi S Sarode; Jayanta K Pal; Nilesh Kumar Sharma
Journal:  Cell Oncol (Dordr)       Date:  2018-07-19       Impact factor: 6.730

Review 3.  Pericytes in the Premetastatic Niche.

Authors:  Ana E Paiva; Luiza Lousado; Daniel A P Guerra; Patrick O Azevedo; Isadora F G Sena; Julia P Andreotti; Gabryella S P Santos; Ricardo Gonçalves; Akiva Mintz; Alexander Birbrair
Journal:  Cancer Res       Date:  2018-05-22       Impact factor: 12.701

Review 4.  Stromal contributions to the carcinogenic process.

Authors:  Mark Spaw; Shrikant Anant; Sufi Mary Thomas
Journal:  Mol Carcinog       Date:  2016-11-05       Impact factor: 4.784

Review 5.  Myeloid-derived suppressor cells and their role in pancreatic cancer.

Authors:  M Pergamo; G Miller
Journal:  Cancer Gene Ther       Date:  2016-12-02       Impact factor: 5.987

6.  Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Authors:  Joao Incio; Jennifer A Ligibel; Daniel T McManus; Priya Suboj; Keehoon Jung; Kosuke Kawaguchi; Matthias Pinter; Suboj Babykutty; Shan M Chin; Trupti D Vardam; Yuhui Huang; Nuh N Rahbari; Sylvie Roberge; Dannie Wang; Igor L Gomes-Santos; Stefan B Puchner; Christopher L Schlett; Udo Hoffmman; Marek Ancukiewicz; Sara M Tolaney; Ian E Krop; Dan G Duda; Yves Boucher; Dai Fukumura; Rakesh K Jain
Journal:  Sci Transl Med       Date:  2018-03-14       Impact factor: 17.956

Review 7.  Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome.

Authors:  Daniel A P Guerra; Ana E Paiva; Isadora F G Sena; Patrick O Azevedo; Walison N Silva; Akiva Mintz; Alexander Birbrair
Journal:  Angiogenesis       Date:  2018-05-14       Impact factor: 9.596

8.  Targeting Glioma Stem Cell-Derived Pericytes Disrupts the Blood-Tumor Barrier and Improves Chemotherapeutic Efficacy.

Authors:  Wenchao Zhou; Cong Chen; Yu Shi; Qiulian Wu; Ryan C Gimple; Xiaoguang Fang; Zhi Huang; Kui Zhai; Susan Q Ke; Yi-Fang Ping; Hua Feng; Jeremy N Rich; Jennifer S Yu; Shideng Bao; Xiu-Wu Bian
Journal:  Cell Stem Cell       Date:  2017-11-02       Impact factor: 24.633

9.  FGF-2 signaling in nasopharyngeal carcinoma modulates pericyte-macrophage crosstalk and metastasis.

Authors:  Yujie Wang; Qi Sun; Ying Ye; Xiaoting Sun; Sisi Xie; Yuhang Zhan; Jian Song; Xiaoqin Fan; Bin Zhang; Ming Yang; Lei Lv; Kayoko Hosaka; Yunlong Yang; Guohui Nie
Journal:  JCI Insight       Date:  2022-05-23

Review 10.  The Emerging Roles of Pericytes in Modulating Tumor Microenvironment.

Authors:  Ruipu Sun; Xiangzhan Kong; Xiaoyi Qiu; Cheng Huang; Ping-Pui Wong
Journal:  Front Cell Dev Biol       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.